NPS PHARMACEUTICALS INC's ticker is P103PS and the CUSIP is 62936P103. A total of 193 filers reported holding NPS PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is 0.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2014 | $394,000 | +55.1% | 11,040 | +13.2% | 0.03% | +57.1% |
| Q3 2014 | $254,000 | -27.8% | 9,750 | -8.5% | 0.02% | -25.0% |
| Q2 2014 | $352,000 | -1.1% | 10,650 | -10.5% | 0.03% | +7.7% |
| Q1 2014 | $356,000 | -41.0% | 11,905 | -40.1% | 0.03% | -44.7% |
| Q4 2013 | $603,000 | -9.5% | 19,860 | -5.1% | 0.05% | -13.0% |
| Q3 2013 | $666,000 | +233.0% | 20,930 | +58.0% | 0.05% | +217.6% |
| Q2 2013 | $200,000 | – | 13,245 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 431,475 | $15,433,000 | 5.92% |
| SECTORAL ASSET MANAGEMENT INC | 1,623,073 | $58,057,000 | 2.60% |
| Palo Alto Investors LP | 1,190,263 | $42,576,000 | 2.50% |
| Fiera Capital (Europe) Ltd. | 426,250 | $3,246,000 | 2.39% |
| BENDER ROBERT & ASSOCIATES | 75,080 | $2,686,000 | 1.76% |
| FCG ADVISORS, LLC | 76,865 | $3,138,000 | 1.55% |
| Penn Capital Management Company, LLC | 857,621 | $30,677,000 | 1.29% |
| NEXT CENTURY GROWTH INVESTORS LLC | 927,285 | $33,168,000 | 1.20% |
| Tekla Capital Management LLC | 625,900 | $22,388,000 | 1.05% |
| Orbimed Advisors | 2,954,900 | $105,697,000 | 1.01% |